Lpath, Inc, a San Diego based therapeutic antibody company quoted on the US OTCBB (LPTN) has announced the initiation of enrolment for its anti-angiogenic antibody product, “iSONEP”. The Phase 1b/2a study is designed to treat retinal pigment epithelium detachment (PED) secondary to wet AMD or polypoidal choroidal vasculopathy (PCV). The drug, built from the company’s proprietary “Immune Y2” drug discovery platform is an ocular formulation of a monoclonal antibody raised against sphingosine-1 phosphate, a bioactive signalling lipid. The therapeutic approach is designed to target the angiogenesis, inflammation and scarring associated with wet AMD.
Lpath Inc initiates Phase 1b/2a trial for iSONEP in retinal detachment and vasculopathy secondary to
- by swdadmin